Jun 3, 2019

DaHui Advises Anji Pharmaceuticals on Acquisition of Late-Stage Clinical Asset

Anji Pharmaceuticals, Inc. announced the acquisition of global development rights for a novel delayed-release formulation of metformin (Metformin DR) from Elcelyx Therapeutics. Metformin DR is an investigational product designed to target metformin delivery to the lower small intestine for the treatment of diabetes.

Based in the global pharmaceutical hubs of Cambridge, MA and Shanghai, China, Anji Pharmaceuticals is focused on tackling high-value pharmaceutical targets validated by human genetics. DaHui represented Anji Pharmaceuticals as its sole legal counsel on this acquisition, with the team being led by partner Zheng Zha and counsel Mark Young.

Newsletter

Subscribe to our newsletter.

Related Services

Healthcare & Life Sciences
Mergers & Acquisitions

Related Lawyers

Related News

Jul 9, 2025

New Partners Join DaHui in Beijing and Shanghai
Read Article

May 12, 2025

Dispute Resolution Ranks DaHui Among Top Firms for Eighth Year in a Row
Read Article

Apr 19, 2025

DaHui Advises on Major Bio-Ethanol Deal in Vietnam, Combined Entity Expected to List on NASDAQ
Read Article

© DaHui Lawyers